News & Updates

Obesity does not increase the likelihood of hospitalization among biologic-treated patients with inflammatory bowel disease (IBD), suggests a recent study.

Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.

Exercise interventions may result in positive outcomes on muscular or cardiorespiratory fitness and quality of life in patients with advanced liver disease, suggest the results of a systematic review.

In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).

There appears to be several ways to reduce the risk of pre-eclampsia and pregnancy-induced hypertension. These include low molecular weight heparin (LMWH), vitamin D supplementation, calcium supplementation, aspirin, and exercise, according to a meta-analysis.

Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.